Hikma Pharmaceuticals PLC
HKMPF · OTC
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.08 | -0.24 | 0.02 | -0.39 |
| FCF Yield | 1.51% | 5.05% | 2.28% | 5.83% |
| EV / EBITDA | 15.74 | 22.46 | 13.41 | 17.82 |
| Quality | ||||
| ROIC | 5.00% | 5.46% | 7.58% | 2.69% |
| Gross Margin | 43.73% | 42.30% | 48.18% | 47.79% |
| Cash Conversion Ratio | 0.68 | 2.75 | 0.88 | 6.54 |
| Growth | ||||
| Revenue 3-Year CAGR | 9.73% | 9.69% | 9.07% | 8.03% |
| Free Cash Flow Growth | -65.56% | 109.30% | -57.14% | 118.12% |
| Safety | ||||
| Net Debt / EBITDA | 2.78 | 3.88 | 2.08 | 2.86 |
| Interest Coverage | 6.12 | 0.00 | 7.98 | 2.79 |
| Efficiency | ||||
| Inventory Turnover | 0.86 | 0.91 | 0.87 | 0.85 |
| Cash Conversion Cycle | 103.46 | 115.15 | 97.47 | 118.33 |